Research programme: eye disorder therapeutics - Imprimis Pharmaceuticals

Drug Profile

Research programme: eye disorder therapeutics - Imprimis Pharmaceuticals

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Imprimis Pharmaceuticals
  • Class Eye disorder therapies; Glucans; Glycerols; Glycosaminoglycans
  • Mechanism of Action Cell membrane structure modulators; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Eye disorders

Most Recent Events

  • 06 Apr 2017 Early research in Eye disorders in USA (Ophthalmic)
  • 06 Apr 2017 Imprimis Pharmaceuticals in-licenses Klarity formulation technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top